Full-Time

Executive Director

Biomarkers

Posted on 7/17/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$276k - $414k/yr

+ Bonus + Equity Grants

Pennsylvania, USA

Remote

Must reside in Pennsylvania, United States; remote from home-based PA.

Category
Biology & Biotech (1)

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Oncology experience is REQUIRED with deep knowledge of tumor biology, heterogeneity, clinical development, and regulatory considerations.
  • Non-oncology biomarker experience is PREFERRED (e.g., neuroscience) to cross-pollinate best practices.
  • Proven track record delivering biomarker strategies and CDx programs, including analytical/clinical validation and regulatory submissions
  • Fluency in multi-omic data (genomics, transcriptomics, proteomics, metabolomics) and molecular assay platforms (IHC/ISH, Next-Generation Sequencing, PCR, flow cytometry, mass spectrometry, circulating tumor DNA)
  • Experience designing correlative science for both clinical trials and nonclinical studies; ability to translate mechanism of action into measurable pharmacodynamic and patient‑selection hypotheses
  • Strong leadership in matrixed environments; ability to influence without authority and manage external partners/CROs
  • Excellent oral and written communication; ability to author and review technical and regulatory documents
  • Education: Doctoral degree (PhD, MD, or MD/PhD) in molecular biology, genomics, bioinformatics, biomedical engineering, or related field, with significant experience in a drug development setting and significant oncology biomarker leadership
  • Preferred: ASCP/MGP or clinical laboratory certifications as applicable
Responsibilities
  • Own the end-to-end biomarker strategy for oncology programs through design, execution, analyzing, and reporting correlative biomarker studies for clinical trials (Phase 0–3) and nonclinical work, including PK/PD, pharmacogenomic, immunophenotyping, and circulating biomarker readouts.
  • Lead Companion Diagnostic strategy: define intended use, select/manage diagnostic partners/CROs, oversee analytical/clinical validation, and align on regulatory pathways (e.g., PMA/510(k), IVDR).
  • Embed patient selection/enrichment strategies and biomarker endpoints into protocols and SAPs in partnership with Clinical Development, Biostatistics, and Regulatory.
  • Author/review biomarker plans, clinical protocols, IB/IND/IMPD sections, CDx submissions, and responses to health authority queries.
  • Establish fit‑for‑purpose assays (tissue and liquid) and data standards; ensure chain‑of‑custody, quality, and compliance for biospecimens and data.
  • Build and lead a high‑performing biomarker team; manage budgets, timelines, vendors, and academic collaborations.
  • Communicate strategy, risks, and recommendations to R&D leadership; represent the company with partners, KOLs, and scientific consortia.
  • Contribute to Search & Evaluation by assessing biomarker/CDx feasibility and translational rationale for external opportunities.
Desired Qualifications
  • Non‑oncology biomarker experience PREFERRED (e.g., neuroscience) to cross‑pollinate best practices.
  • Proven track record delivering biomarker strategies and CDx programs, including analytical/clinical validation and regulatory submissions
  • ASCP/MGP or clinical laboratory certifications (preferred)

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 2025 revenue reached $4.3 billion, with Xywav at $1.7 billion.
  • Zepzelca's first-line maintenance approval opened a new commercial growth avenue.
  • Xywav's orphan exclusivity and superiority findings support pricing power and share defense.

What critics are saying

  • Xywav concentration makes FDA, payer, or clinical setbacks disproportionately damaging.
  • Zepzelca's failed second-line trial weakens longer-term expansion beyond first-line maintenance.
  • High debt and 0.7% margins leave little cushion for execution misses.

What makes Jazz Pharmaceuticals unique

  • Jazz combines neuroscience and oncology across rare, hard-to-treat diseases.
  • Xywav and Epidiolex anchor a concentrated sleep-and-epilepsy franchise.
  • Jazz uses acquisitions, including GW Pharmaceuticals and Chimerix, to build its pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE